Literature DB >> 26968636

Targeting the replisome with transduced monoclonal antibodies triggers lethal DNA replication stress in cancer cells.

Dominique Desplancq1, Guillaume Freund1, Sascha Conic2, Annie-Paule Sibler1, Pascal Didier3, Audrey Stoessel1, Mustapha Oulad-Abdelghani2, Marc Vigneron1, Jérôme Wagner1, Yves Mély3, Bruno Chatton1, Laszlo Tora2, Etienne Weiss4.   

Abstract

Although chemical inhibition of the DNA damage response (DDR) in cancer cells triggers cell death, it is not clear if the fork blockade achieved with inhibitors that neutralise proteins of the replisome is sufficient on its own to overcome the DDR. Monoclonal antibodies to PCNA, which block the DNA elongation process in vitro, have been developed. When these antibodies were transduced into cancer cells, they are able to inhibit the incorporation of nucleoside analogues. When co-delivered with anti-PCNA siRNA, the cells were flattened and the size of their nuclei increased by up to 3-fold, prior to cell death. Analysis of these nuclei by super-resolution microscopy revealed the presence of large numbers of phosphorylated histone H2AX foci. A senescence-like phenotype of the transduced cells was also observed upon delivery of the corresponding Fab molecules or following PCNA gene disruption or when the Fab fragment of an antibody that neutralises DNA polymerase alpha was used. Primary melanoma cells and leukaemia cells that are resistant to chemical inhibitors were similarly affected by these antibody treatments. These results demonstrate that transduced antibodies can trigger a lethal DNA replication stress, which kills cancer cells by abolishing the biological activity of several constituents of the replisome.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibody transduction; Chemo-resistant cancer cells; DNA polymerase alpha; DNA replication stress; Functional inhibition; Proliferating cell nuclear antigen

Mesh:

Substances:

Year:  2016        PMID: 26968636     DOI: 10.1016/j.yexcr.2016.03.003

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  9 in total

1.  Cell-permeable nanobodies for targeted immunolabelling and antigen manipulation in living cells.

Authors:  Henry D Herce; Dominik Schumacher; Anselm F L Schneider; Anne K Ludwig; Florian A Mann; Marion Fillies; Marc-André Kasper; Stefan Reinke; Eberhard Krause; Heinrich Leonhardt; M Cristina Cardoso; Christian P R Hackenberger
Journal:  Nat Chem       Date:  2017-07-17       Impact factor: 24.427

2.  Electroporation of Labeled Antibodies to Visualize Endogenous Proteins and Posttranslational Modifications in Living Metazoan Cell Types.

Authors:  Sascha Conic; Dominique Desplancq; László Tora; Etienne Weiss
Journal:  Bio Protoc       Date:  2018-11-05

3.  Imaging of native transcription factors and histone phosphorylation at high resolution in live cells.

Authors:  Sascha Conic; Dominique Desplancq; Alexia Ferrand; Veronique Fischer; Vincent Heyer; Bernardo Reina San Martin; Julien Pontabry; Mustapha Oulad-Abdelghani; Kishore Babu N; Graham D Wright; Nacho Molina; Etienne Weiss; László Tora
Journal:  J Cell Biol       Date:  2018-02-12       Impact factor: 10.539

Review 4.  Nanobodies: Chemical Functionalization Strategies and Intracellular Applications.

Authors:  Dominik Schumacher; Jonas Helma; Anselm F L Schneider; Heinrich Leonhardt; Christian P R Hackenberger
Journal:  Angew Chem Int Ed Engl       Date:  2018-01-26       Impact factor: 15.336

Review 5.  Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.

Authors:  Congcong Zhang; Rina M Ötjengerdes; Julian Roewe; Rebeca Mejias; Andrea L J Marschall
Journal:  BioDrugs       Date:  2020-08       Impact factor: 5.807

Review 6.  Targeted Intracellular Delivery of Antibodies: The State of the Art.

Authors:  Tatiana A Slastnikova; A V Ulasov; A A Rosenkranz; A S Sobolev
Journal:  Front Pharmacol       Date:  2018-10-24       Impact factor: 5.810

7.  Additive effects of a small molecular PCNA inhibitor PCNA-I1S and DNA damaging agents on growth inhibition and DNA damage in prostate and lung cancer cells.

Authors:  Shan Lu; Zhongyun Dong
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

Review 8.  Antibodies inside of a cell can change its outside: Can intrabodies provide a new therapeutic paradigm?

Authors:  Andrea L J Marschall; Stefan Dübel
Journal:  Comput Struct Biotechnol J       Date:  2016-07-31       Impact factor: 7.271

9.  Cytosolic PCNA interacts with p47phox and controls NADPH oxidase NOX2 activation in neutrophils.

Authors:  Delphine Ohayon; Alessia De Chiara; Pham My-Chan Dang; Nathalie Thieblemont; Simon Chatfield; Viviana Marzaioli; Sabrina Sofia Burgener; Julie Mocek; Céline Candalh; Coralie Pintard; Pascale Tacnet-Delorme; Gilles Renault; Isabelle Lagoutte; Maryline Favier; Francine Walker; Margarita Hurtado-Nedelec; Dominique Desplancq; Etienne Weiss; Charaf Benarafa; Dominique Housset; Jean-Claude Marie; Philippe Frachet; Jamel El-Benna; Véronique Witko-Sarsat
Journal:  J Exp Med       Date:  2019-09-06       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.